PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6354
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis ; volume:15 ; number:6 ; day:4 ; month:12 ; year:2013 ; pages:1-15 ; date:12.2013
Arthritis Research & Therapy ; 15, Heft 6 (4.12.2013), 1-15, 12.2013
- Urheber
-
Woo, Jacky
- Beteiligte Personen und Organisationen
-
Vierboom, Michel PM
Kwon, Hakju
Chao, Debra
Ye, Shiming
Li, Jianmin
Lin, Karen
Tang, Irene
Belmar, Nicole A.
Hartman, Taymar
Breedveld, Elia
Vexler, Vladimir
‘t Hart, Bert A.
Law, Debbie A.
Starling, Gary C.
SpringerLink (Online service)
- DOI
-
10.1186/ar4400
- URN
-
urn:nbn:de:1111-2016051825146
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Woo, Jacky
- Vierboom, Michel PM
- Kwon, Hakju
- Chao, Debra
- Ye, Shiming
- Li, Jianmin
- Lin, Karen
- Tang, Irene
- Belmar, Nicole A.
- Hartman, Taymar
- Breedveld, Elia
- Vexler, Vladimir
- ‘t Hart, Bert A.
- Law, Debbie A.
- Starling, Gary C.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments
Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis
Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513
MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments
IC100, a humanized therapeutic monoclonal anti-ASC antibody alleviates oxygen-induced retinopathy in mice
Development of a humanized anti-FABP4 monoclonal antibody for potential treatment of breast cancer
High thioredoxin-1 levels in rheumatoid arthritis patients diminish binding and signalling of the monoclonal antibody Tregalizumab
A fully human connective tissue growth factor blocking monoclonal antibody ameliorates experimental rheumatoid arthritis through inhibiting angiogenesis
Monoclonal antibody therapy
Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency
2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus
Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis
Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments
Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis
Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513
MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments
IC100, a humanized therapeutic monoclonal anti-ASC antibody alleviates oxygen-induced retinopathy in mice
Development of a humanized anti-FABP4 monoclonal antibody for potential treatment of breast cancer
High thioredoxin-1 levels in rheumatoid arthritis patients diminish binding and signalling of the monoclonal antibody Tregalizumab
A fully human connective tissue growth factor blocking monoclonal antibody ameliorates experimental rheumatoid arthritis through inhibiting angiogenesis
Monoclonal antibody therapy
Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency
2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus
Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis
Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments
Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis
Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513
MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments
IC100, a humanized therapeutic monoclonal anti-ASC antibody alleviates oxygen-induced retinopathy in mice
Development of a humanized anti-FABP4 monoclonal antibody for potential treatment of breast cancer
High thioredoxin-1 levels in rheumatoid arthritis patients diminish binding and signalling of the monoclonal antibody Tregalizumab
A fully human connective tissue growth factor blocking monoclonal antibody ameliorates experimental rheumatoid arthritis through inhibiting angiogenesis
Monoclonal antibody therapy
Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency
2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus